Novartis Buys Rights to Intecell's Japanese Encephalitis Vaccine Candidate
Filed in archive Corporate and Industrial News , Drugs, Vaccines and Therapeutics on June 14, 2006
Novartis is buying rights to Austrian biotech firm Intercell AG's IC51 experimental vaccine against the tropical disease Japanese encephalitis. IC51 will be an addition to Novartis' portfolio of travel vaccines, which include prophylaxis against diseases such as Hepatitis A, cholera and typhoid fever.
Intercell recently announced favorable results for IC51 in Phase III clinical trials and the vaccine is currently under regulatory review in Europe with an orphan drug status.
Further details from Market Watch.
Tags: vaccine encephalitis biotech novartis rights japanese+encephalitis vaccine+candidate novartis+buys
Vote for Novartis Buys Rights to Intecell's Japanese Encephalitis Vaccine Candidate:
|
Rating: 9.50 out of 4 vote(s) cast.
|
| RSS |  |
 | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
Most Popular
Best of
Biotech Hubs and Facilities
Biotech/Science Blogs
Corporate and Industrial News
Diagnostics, Methodologies and Instrumentation
Did you know
Drugs, Vaccines and Therapeutics
Energy, Environment and Ecology
Food and Agriculture
Gene Therapy
Genomics, Proteomics and Bioinformatics
Information About
Meetings and Other Events
Microbiology
Misc
Nanomedicine
Other Biotechnology News
Patents and Intellectual Property Rights
Quick introduction
Stem Cells